Curated Wealth Partners LLC Cuts Holdings in Johnson & Johnson $JNJ

Curated Wealth Partners LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.6% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 2,263 shares of the company’s stock after selling 134 shares during the quarter. Curated Wealth Partners LLC’s holdings in Johnson & Johnson were worth $346,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Apexium Financial LP increased its holdings in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after buying an additional 2,310 shares during the period. Avanza Fonder AB increased its holdings in Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after buying an additional 6,566 shares during the period. Joel Isaacson & Co. LLC increased its holdings in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after buying an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its holdings in Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after buying an additional 4,816 shares during the period. Finally, Absher Wealth Management LLC grew its holdings in Johnson & Johnson by 1.2% in the first quarter. Absher Wealth Management LLC now owns 215,584 shares of the company’s stock worth $35,752,000 after purchasing an additional 2,469 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several analyst reports. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Argus set a $210.00 price target on shares of Johnson & Johnson in a report on Wednesday. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $199.59.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.3%

NYSE JNJ opened at $191.79 on Friday. The company has a market capitalization of $461.90 billion, a PE ratio of 18.51, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a fifty day moving average of $180.09 and a 200 day moving average of $164.52. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.